---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001322"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:40:49.440014+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika Q4 revenue $43.0M (+8%), net loss incl. $62.2M impairment; guides FY2024 adj. EBITDA $25-30M

## Summary
- Q4 revenue $43.0M (+8% YoY); net loss ($63.0M) or ($4.30)/share due to $62.2M non-cash impairment on Arthrosurface/Parcus intangibles.
- FY2023 revenue $166.7M (+7% YoY); OA Pain Management record $101.9M (+11%).
- Announces ~9% workforce reduction expected to save ~$10 million annually in 2024.
- FY2024 guidance: revenue $168-173M (+1-4%), adj. EBITDA $25-30M (margin at least 15%), up >75% at midpoint.
- Engaged Piper Sandler for strategic review, evaluating alternatives including potential sale.

## SEC filing metadata
- accession: 0001171843-24-001322
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/f8k_031324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001322
- JSON: https://secwatch.observer/filing/0001171843-24-001322.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001322.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: revenue $166.7 million, net income ($82.7) million, EPS ($5.64) per share. Guidance initiated.
  - Period: fiscal year ended December 31, 2023
  - Revenue: $166.7 million
  - Net income: ($82.7) million
  - EPS: ($5.64) per share
  - Guidance: initiated
  - Result: reported results
  source text: Revenue for fiscal 2023 increased 7% to $166.7 million, compared with $156.2 million in 2022. OA Pain Management revenue of $101.9 million, up 11% Joint Preservation and Restoration revenue of $54.9 million, up 9% Non-Orthopedic revenue of $9.9 million, down 29% Gross margin was 62%, including $6.2 million of non-cash acquisition-related intangible asset amortization and $0.7 million of product rationalization charges. Adjusted gross margin 1 , excluding these charges, was 66%. Including the fourth quarter non-cash impairment charge, net loss was ($82.7) million, or ($5.64) per share, compared to net loss of ($14.9) million, or ($1.02) per share, in 2022. Net loss also included $18.1 million, or ($1.23) per share, for charges associated with product rationalization, acquisition related amortization, discontinuation of software development, Parcus arbitration settlement and shareholder activism. Adjusted net loss 1 for the year was ($4.3) million, or ($0.30) per share, compared to adjus
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm
- Earnings Releases
  Anika Therapeutics, Inc. reported fourth quarter ended December 31, 2023 results: revenue $43.0 million, net income ($63.0) million, EPS ($4.30) per share. Guidance initiated.
  - Period: fourth quarter ended December 31, 2023
  - Revenue: $43.0 million
  - Net income: ($63.0) million
  - EPS: ($4.30) per share
  - Guidance: initiated
  - Result: reported results
  source text: Revenue in the fourth quarter of 2023 was $43.0 million, up 8% compared to $39.6 million in the fourth quarter of 2022. OA Pain Management revenue of $25.1 million, up 12%, on growing global commercial adoption and some order timing Joint Preservation and Restoration revenue of $15.3 million, up 7% Non-Orthopedic revenue of $2.6 million, down 8% Gross margin was 61%, including $1.6 million of non-cash acquisition-related intangible asset amortization; Adjusted gross margin 1 was 65%. Recorded a non-recurring, non-cash impairment charge in the fourth quarter of $62.2 million for the intangible assets associated with the Q1-2020 acquisitions of Arthrosurface and Parcus Medical. Including the non-cash impairment charge, net loss was ($63.0) million, or ($4.30) per share, compared to net loss of ($4.9) million, or ($0.34) per share, in the prior year period. Adjusted net income 1 was $0.8 million, or $0.05 per diluted share, compared to adjusted net loss 1 of ($3.0) million, or ($0.21) per
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324001322/0001171843-24-001322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.